Adults with type 1 diabetes prioritize HbA1c time-in-target-range, weight loss and simple treatment procedures when evaluating their diabetes care, and there may be a substantial willingness to use adjunct therapies to achieve these goals, according to findings published in Diabetes Technology & Therapeutics .
“Despite these continued advances in management, particularly in the types of devices available, type 1 diabetes remains a constant daily burden for patients,” Jeremy H. Pettus, MD , an assistant clinical professor of medicine in the School of Health Sciences at the University of California, San Diego, in La Jolla, California, and colleagues wrote. “When navigating the risk-benefit ratio, it is important to realize that patients’ and health care providers’ views may differ on the importance of individual risk and benefit factors.”
To assess treatment preferences, Pettus and colleagues sent a survey and received responses from 1,313 adults (median age, 53 years; 67% women) with type 1 diabetes in November 2017. Participants were asked to rate how important and satisfied they were with achieving 15 different outcomes from diabetes treatment. Outcomes included maintaining daytime blood glucose between 70 mg/dL and 180 mg/dL, keeping HbA1c within target range and avoiding severe hypoglycemic events. The survey also included a section in which participants were asked their preference for either insulin only or the addition of 200 mg or 400 mg sotagliflozin (Sanofi/Lexicon) assuming the benefits expected based on clinical trials.
Read the ENTIRE post HERE!